The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: A randomised controlled trial

Diabetologia

Volumn 57, Issue 5, 2014, Pages 878-890

  Takeshita, Yumie ^a   Takamura, Toshinari ^a   Honda, Masao ^a   Kita, Yuki ^a   Zen, Yoh ^b   Kato, Ken Ichiro ^a   Misu, Hirofumi ^a   Ota, Tsuguhito ^a   Nakamura, Mikiko ^a   Yamada, Kazutoshi ^a   Sunagozaka, Hajime ^a   Arai, Kuniaki ^a   Yamashita, Tatsuya ^a   Mizukoshi, Eishiro ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Ezetimibe; Fatty acid; Gene expression; Non alcoholic fatty liver disease

Indexed keywords

AMINOTRANSFERASE; CARNITINE; CHOLESTEROL; EZETIMIBE; GLUCOSE; HEMOGLOBIN A1C; LONG CHAIN FATTY ACID; AZETIDINE DERIVATIVE; FATTY ACID; GLYCOSYLATED HEMOGLOBIN; HYPOCHOLESTEROLEMIC AGENT; INSULIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; INSULIN SENSITIVITY; LIVER FIBROSIS; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPREGULATION; AGED; AREA UNDER THE CURVE; BIOPSY; BLOOD; CHEMISTRY; DNA MICROARRAY; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION PROFILING; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; LIVER; METABOLISM; MYOFIBROBLAST; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; AZETIDINES; BIOPSY; CARNITINE; CHOLESTEROL; FATTY ACIDS; FEMALE; FIBROSIS; GENE EXPRESSION PROFILING; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LIVER; MALE; MIDDLE AGED; MYOFIBROBLASTS; NON-ALCOHOLIC FATTY LIVER DISEASE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TRANSAMINASES; TREATMENT OUTCOME;

EID: 84898600580     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-3149-9     Document Type: Article

References (41)

1. Hamaguchi E, Takamura T, Sakurai M et al (2010) Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 33:284-286
2. Sakurai M, Takamura T, Ota T et al (2007) Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. J Gastroenterol 42:312-317 (Pubitemid 46681707)
3. Matsuzawa N, Takamura T, Kurita S et al (2007) Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46:1392-1403 (Pubitemid 350155521)
4. Marí M, Caballero F, Colell A et al (2006) Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 4:185-198 (Pubitemid 44307975)
5. Nakamura S, Takamura T, Matsuzawa-Nagata N et al (2009) Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J Biol Chem 29:14809-14818
6. Garcia-Calvo M, Lisnock J, Bull HG et al (2005) The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1). Proc Natl Acad Sci U S A 102:8132-8137 (Pubitemid 40800055)
7. Muraoka T, Aoki K, Iwasaki T et al (2011) Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 60:617-628
8. Deushi M, Nomura M, Kawakami A et al (2007) Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 581:5664-5670 (Pubitemid 350179776)
9. Yoneda M, Fujita K, Nozaki Y et al (2010) Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 40:613-621
10. Park H, Shima T, Yamaguchi K et al (2011) Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 46:101-107
11. Promrat K, Lutchman G, Uwaifo GI et al (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-196 (Pubitemid 38461481)
12. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
13. Katz A, Nambi SS, Mather K et al (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410 (Pubitemid 32269192)
14. Musso G, Cassader M, de Michieli F, Rosina F, Orlandi F, Gambino R (2012) Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 56:933-942
15. Musso G, Cassader M, Bo S, de Michieli F, Gambino R (2013) Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes 62:1109-1120
16. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA (2007) Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133:496-506 (Pubitemid 47187337)
17. Musso G, Gambino R, Cassader M (2010) Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. J Nutr Biochem 21:834-840
18. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M (2007) What is the best predictor of future type 2 diabetes? Diabetes Care 30:1544-1548 (Pubitemid 46871168)
19. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470 (Pubitemid 29418240)
20. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA (2007) Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 30:89-94 (Pubitemid 46052504)
21. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
22. Nagai Y, Takamura T, Nohara E et al (1999) Acute hyperinsulinemia reduces plasma concentrations of homocysteine in healthy men. Diabetes Care 22:1004 (Pubitemid 29241064)
23. Brunt EM, Janney CG, Di Bisceglie AM et al (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474 (Pubitemid 29420675)
24. Kleiner DE, Brunt EM, van Natta M et al (2005) Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321 (Pubitemid 40770284)
25. DeBose-Boyd RA, Ou J, Goldstein JL, Brown MS (2001) Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc Natl Acad Sci U S A 13:1477-1482 (Pubitemid 32165524)
26. de Bari O, Neuschwander-Tetri BA, Liu M et al (2012) Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic fatty liver disease. J Lipids 2012:302847
27. Jia L, Ma Y, Rong S et al (2010) Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. J Lipid Res 51:3135-3144
28. Musso G, Gambino R, Cassader M (2013) Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 52:175-191
29. Teratani T, Tomita K, Suzuki T et al (2012) A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 142:152-164
30. Altmann SW, Davis HR Jr, Zhu LJ et al (2004) Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201-1204 (Pubitemid 38233587)
31. Temel RE, Brown JM, Ma Y et al (2007) Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 117:1968-1978 (Pubitemid 47036331)
32. Joshi-Barve S, Barve SS, Amancherla K et al (2007) Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 46:823-830 (Pubitemid 47436129)
33. Pagliassotti MJ, Wei Y, Wang D (2007) Insulin protects liver cells from saturated fatty acid-induced apoptosis via inhibition of c-Jun NH2 terminal kinase activity. Endocrinology 148:3338-3345 (Pubitemid 46996986)
34. Malhi H, Bronk SF, Werneburg NW, Gores GJ (2006) Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 281:12093-12101 (Pubitemid 43855473)
35. Gerin I, Clerbaux LA, Haumont O et al (2010) Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 285:33652-33661
36. Louet JF, Hayhurst G, Gonzalez FJ et al (2002) The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB). J Biol Chem 277:37991-38000 (Pubitemid 35154650)
37. Xuefen X, Hailing L, Huaixin D et al (2009) Down-regulation of hepatic HNF4- gene expression during hyperinsulinemia via SREBPs. Mol Endocrinol 23:434-443
38. Horie T, Ono K, Horiguchi M et al (2010) MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A 107:17321-17326
39. Fernández-Hernando C, Moore KJ (2011) MicroRNA modulation of cholesterol homeostasis. Arterioscler Thromb Vasc Biol 31:2378-2382
40. Musso G, Cassader M, Rosina F, Orlandi F, Gambino R (2012) Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55:885-904
41. Bennett MK, Seo YK, Datta S, Shin DJ, Osborne TF (2008) Selective binding of sterol regulatory element-binding protein isoforms and co-regulatory proteins to promoters for lipid metabolic genes in liver. J Biol Chem 6:15628-15637